Guillaume Grisay, Fabio Turco, Anna Patrikidou, Enrique Gallardo, Ray McDermott, Erik Briers, Beatrice Fournier, Olga Basova, Bert Dhont, Marcell Csanádi, Silke Gillessen, Bertrand Tombal
For patients with metastatic hormone-sensitive prostate cancer who achieve deep prostate-specific antigen responses with androgen deprivation therapy plus an androgen receptor pathway inhibitor, continuous treatment until progression may not be necessary. EORTC 2238 tests whether an intermittent strategy can safely reduce toxicity, improve quality of life, and lessen health care resource use.